Effects of α1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: Relationships to uroselectivity

European Journal of Pharmacology

Volumn 373, Issue 1, 1999, Pages 51-62

  Hieble, J Paul ^a   Kolpak, David C ^a   McCafferty, Gerald P ^a   Ruffolo Jr , Robert R ^a   Testa, Rodolfo ^b   Leonardi, Amedeo ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Pharmaceutical R and D Division   (Italy)

Author keywords

Benign prostatic hyperplasia; Diastolic blood pressure; Orthostatic hypotension; Urethral perfusion pressure

Indexed keywords

8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; 8 [3 [4 (5 CHLORO 2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 2 CYCLOHEXYL 3 METHYL 4H 1 BENZOPYRAN 4 ONE; 8 [3 [4 (5 CHLORO 2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; DOXAZOSIN; PHENYLEPHRINE; PRAZOSIN; REC 15 2841; SL 890591; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; QUINAZOLINE DERIVATIVE; REC 15-2739;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG POTENCY; DRUG SELECTIVITY; HYPOTENSION; HYPOVOLEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PERFUSION PRESSURE; PRESSOR RESPONSE; PRIORITY JOURNAL; RABBIT; RAT; SEDATION; SPINAL ANIMAL; TILTING; URETHRA PRESSURE; ANESTHESIA; ANIMAL; BLOOD PRESSURE; BODY POSTURE; CHEMISTRY; CONSCIOUSNESS; DECEREBRATION; DIASTOLE; DOSE RESPONSE; DRUG EFFECT; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; URETHRA;

ADRENERGIC AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANESTHESIA; ANIMALS; BLOOD PRESSURE; CHROMONES; CONSCIOUSNESS; DECEREBRATE STATE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPNOTICS AND SEDATIVES; HYPOTENSION, ORTHOSTATIC; MALE; PHENYLEPHRINE; POSTURE; QUINAZOLINES; RABBITS; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; URETHRA;

EID: 0032587973     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00227-7     Document Type: Article

References (31)

1. 1A-adrenergic antagonist. Urology. 51:1998;861-872.
2. 1-adrenoceptor antagonists in dog prostate/blood pressure models. FASEB J. 10:1996;A425.
3. 1-adrenoceptor antagonist tamsulosin. Am. J. Urol. 157:1997;190. Suppl.
4. Brune M.E., Katwala S.P., Milicic I., Buckner S.A., Ireland L.M., Kerwin J.F. Jr., Hancock A.A. Effects of selective and nonselective alpha-1 adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. Pharmacology. 53:1996;356-368.
5. 1a adrenoceptors. Pharmacologist. 39:1997;44.
6. Eri L.M., Tveter K.J. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 154:1995;923-934.
7. 1C subtype. Mol. Pharmacol. 45:1994;703-708.
8. 1-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur. J. Med. Chem. 30:1995;299s-310s. Suppl.
9. 1C specific compounds to treat benign prostatic hyperplasia. US Patent No. 5,403,847, April 4.
10. Hieble J.P., Ruffolo R.R. The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol. Res. 33:1996;145-160.
11. 2-adrenoceptor subtypes: therapeutic implications. Expert Opinion on Investigational Drugs. 6:1997;367-387.
12. 2-adrenoceptor. Proceedings of the Fifth Vascular Neuroeffector Symposium. In: Bevan, J.A., et al. (Eds.), Vascular Neuroeffector Mechanisms. Elsevier, pp. 159-164.
13. 1-adrenoceptor subtypes in vascular and urogenital tissues. Proceedings of the International Continence Society, Monduzzi Editore, Bologna, pp. 101-105.
14. 1L-Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br. J. Pharmacol. 123:1998;1359-1366.
15. 1-adrenoceptor antagonists on blood pressure and prostatic pressure in the anesthetized dog. Urology. 44:1994;52-57.
16. 1-adrenoceptors: binding, functional and in vivo studies. Br. J. Pharmacol. 118:1996;871-878.
17. Kenny B., Ballard S., Blagg J., Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. 40:1997;1293-1315.
18. 1-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br. J. Urol. 80:1997;606-611.
19. 1-Adrenoceptors: subtype and organ selectivity of different agents. In: Giardina, D., Piergentili, A., Pigini, M. (Eds.), Perspective in Receptor Research. Elsevier, pp. 246-263.
20. 1L adrenoceptor in tissue selectivity. J. Pharmacol. Exp. Ther. 271:1997;1272-1283. Part I.
21. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 51:1998;892-900.
22. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo controlled double-blind extension of phase III trial. Urology. 51:1998;901-906.
23. Lepor H., Williford W.O., Barry M.J., Brawer M.J., Dixon C.M., Gormley G., Haakenson C., Machi M., Narayan P., Padley R.J. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N. Engl. J. Med. 335:1996;533-539.
24. Lepor H., Kaplan S.A., Klimberg I., Mobley D.F., Fawzy A., Gaffney M., Ice K., Dias N. Doxazosin for benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. J. Urol. 157:1997;525-530.
25. Martin D.J., Lluel P., Guillot E., Coste A., Jammes D., Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J. Pharmacol. Exp. Ther. 282:1997;228-235.
26. 1a-adrenoceptor antagonist. Eur. Urol. 29:1996;145-154.
27. 1-adrenoceptor antagonist selective for the lower urinary tract: in vivo studies. Neurourol. Urodyn. 13:1994;471-473.
28. 1-adrenoceptor antagonist. Pharmacol. Commun. 6:1995;79-86.
29. 1L adrenoceptor subtype. Neurourol. Urodyn. 15:1996;346-347.
30. Testa R., Guarneri L., Taddei C., Poggesi E., Angelico P., Sartani A., Leonardi A., Gofrit O.N., Meretyk S., Caine M. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J. Pharmacol. Exp. Ther. 277:1996;1237-1246.
31. 1L adrenoceptor in tissue selectivity. J. Pharmacol. Exp. Ther. 281:1997;1272-1283. Part II.